Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer

25 Jun 2021

Abstract excerpt

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC is characterized by gain of neuroendocrine markers and loss of androgen receptor (AR), making it resistant to current therapeutic strategies targeting the AR signaling axis. Here, we report that MCM2, MCM3, MCM4,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mass Spectrometry Techniques and Applications
Share to Prostate Cancer Treatment and Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34172788
DOI: 10.1038/s41598-021-92552-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancerPMID 34172788Read ↗

Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancerSemantic proximity Read ↗

MCM7 amplification and overexpression are associated with prostate cancer progressionSemantic proximity Read ↗

The MCM Complex: Its Role in DNA Replication and Implications for Cancer TherapySemantic proximity Read ↗

Pan-Cancer Multi-Omics Analysis of Minichromosome Maintenance Proteins (MCMs) Expression in Human CancersSemantic proximity Read ↗

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.Semantic proximity Read ↗

MCM family in gastrointestinal cancer and other malignancies: From functional characterization to clinical implicationSemantic proximity Read ↗

MCM2 in human cancer: functions, mechanisms, and clinical significanceSemantic proximity Read ↗

BI-2536 Promotes Neuroblastoma Cell Death via Minichromosome Maintenance Complex Components 2 and 10Semantic proximity Read ↗

Elevated expression of minichromosome maintenance 3 indicates poor outcomes and promotes G1/S cell cycle progression, proliferation, migration and invasion in colorectal cancerSemantic proximity Read ↗

Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA ReplicationSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.